HeiQ Launches Viroblock NPJ03 for Combating Coronavirus
HeiQ announces that it offers proprietary formulation technology, HeiQ Viroblock NPJ03, an antimicrobial textile treatment tested effective against coronavirus, to its peers, calling for a united effort to help fight the global pandemic.
HeiQ announces that it offers proprietary formulation technology, HeiQ Viroblock NPJ03, an antimicrobial textile treatment tested effective against coronavirus, to its peers, calling for a united effort to help fight the global pandemic.
Striving to help advance the global fight against coronavirus on textiles, HeiQ recently launched HeiQ Viroblock NPJ03, an antimicrobial textile treatment proven effective against human coronavirus (229E) in face mask testing, significantly enhancing the antiviral log reduction from 2.90 of untreated face masks to 4.5, a 30 times improvement with over 99.99% reduction of virus infectivity in minutes. It is tested to last at least 30 washes. Since its launch the company has been utilizing its full capacity of 145 tons per day in its four manufacturing sites on three continents.
In his interview with CNN, HeiQ co-founder and Group CEO Carlo Centonze expressed the urgent need to maximize the impact of the international textile industry in fighting the global pandemic, even if that meant sharing HeiQ’s proprietary technology. HeiQ has since offered to share its HeiQ Viroblock NPJ03 technology to textile industry peers via a free licence. Sharing the formula, manufacturing protocol and technical guidance will permit the manufacture and commercialization of HeiQ Viroblock NPJ03 to meet the regulatory compliance and performance requirement. Licensees will be required to test their treated fabrics with licensed third-party testing institutes to establish efficacy and quality as per HeiQ’s standards. Use of the “HeiQ Viroblock” trademark in relation to treated articles will require trademark authorization directly by HeiQ to ensure truthful and compliant claims.
“There is not a moment to lose. We must act now and act fast to produce textiles for hospitals and every frontline healthcare worker that are more resistant to pathogenic viruses and bacteria. The international textile industry must do our part and work together in a united effort to protect textiles and help in the struggle to reduce the risk and speed of contamination and transmission around the world”, says Carlo Centonze, HeiQ Group CEO. “Reducing transmission and infection rates is the only way to re-open our economies swiftly and maintain jobs in the textile industry,” he added.
Ralf Kattanek, Group Vice President Textiles of CHT Group said, “We believe by using CHT’s textile expertise and production capacities globally that we can play a key role in mitigating the impact for the healthcare workers and our industry partners by maximizing our reach swiftly.”
David Juang, Chairman of Taiwanese textile chemicals manufacturer JINTEX Group adds “We want to show leadership in taking decisive action in a coordinated effort.”
Striving to help advance the global fight against coronavirus on textiles, HeiQ recently launched HeiQ Viroblock NPJ03, an antimicrobial textile treatment proven effective against human coronavirus (229E) in face mask testing, significantly enhancing the antiviral log reduction from 2.90 of untreated face masks to 4.5, a 30 times improvement with over 99.99% reduction of virus infectivity in minutes. It is tested to last at least 30 washes. Since its launch the company has been utilizing its full capacity of 145 tons per day in its four manufacturing sites on three continents.
In his interview with CNN, HeiQ co-founder and Group CEO Carlo Centonze expressed the urgent need to maximize the impact of the international textile industry in fighting the global pandemic, even if that meant sharing HeiQ’s proprietary technology. HeiQ has since offered to share its HeiQ Viroblock NPJ03 technology to textile industry peers via a free licence. Sharing the formula, manufacturing protocol and technical guidance will permit the manufacture and commercialization of HeiQ Viroblock NPJ03 to meet the regulatory compliance and performance requirement. Licensees will be required to test their treated fabrics with licensed third-party testing institutes to establish efficacy and quality as per HeiQ’s standards. Use of the “HeiQ Viroblock” trademark in relation to treated articles will require trademark authorization directly by HeiQ to ensure truthful and compliant claims.
“There is not a moment to lose. We must act now and act fast to produce textiles for hospitals and every frontline healthcare worker that are more resistant to pathogenic viruses and bacteria. The international textile industry must do our part and work together in a united effort to protect textiles and help in the struggle to reduce the risk and speed of contamination and transmission around the world”, says Carlo Centonze, HeiQ Group CEO. “Reducing transmission and infection rates is the only way to re-open our economies swiftly and maintain jobs in the textile industry,” he added.
Ralf Kattanek, Group Vice President Textiles of CHT Group said, “We believe by using CHT’s textile expertise and production capacities globally that we can play a key role in mitigating the impact for the healthcare workers and our industry partners by maximizing our reach swiftly.”
David Juang, Chairman of Taiwanese textile chemicals manufacturer JINTEX Group adds “We want to show leadership in taking decisive action in a coordinated effort.”
by sourcing: www.etextilemagazine.com
We want to source Heiq Viroblock NPJ03. Is there any dealer for this chemical in India. If so, please give the Company’s name, contact person and mobile number. Please contact me on +91-9912016000
K. Rajendra Chetty
CEO
Srivari Industries (Mfrs. of Spunbond nonwoven fabrics)
Tirupati.
Hello Tirupati,
as Heiq Viroblock NPJ03 is under processing to bulk production for any new item. you could contact direct with them to get it.
it is too helpfull